Clinical Management of Non-Traumatic Intracerebral Haemorrhage

Husayn Al Mahdy BM*
Common Lane, Titchfield, Hampshire, PO14 4DA, United Kingdom

*Corresponding author: Dr. Husayn Al Mahdy BM, MRCP (UK), Consultant Physician, Yeovil District Hospital NHS Foundation Trust, Stroke Medicine, Higher Kingston, Yeovil Somerset, Yeovil, Somerset BA21 4AT, United Kingdom, Tel: +447961903199; E-mail: pablomartinez400@hotmail.com

Rec date: Jan 19, 2016; Acc date: Jan 27, 2016; Pub date: Jan 29, 2016

Copyright: © 2016 Al Mahdy HBM. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Introduction

Non-traumatic intracerebral hemorrhage is a feared entity when it presents to stroke physicians. It tends to have a higher mortality than ischemic stroke and it is the least known form of cerebrovascular event simply because little research has been undertaken in the past few decades. But the circumstances are changing with more focused studies completed in the last few years and some are on-going. This article will provide a very brief overview of the state of progress in the clinical management of non-traumatic intracerebral hemorrhage.

Because of the poor prognosis of this entity aggressive clinical measures need to be taken for its management as most of the morbidity and mortality is from haematoma expansion which occurs early in the presentation coupled with medical complications [1]. Haematoma expansion can be predicted by undertaking computed tomography (CT) angiogram of head in addition to non-contrasted CT of head [2]. The ‘Spot Sign’-a feature of seeping of the contrast into the haematoma suggests haematoma expansion which reflects a poor functional outcome and increased mortality. The CT head angiography may also provide early diagnosis of underlying vascular malformation which would influence early management of intracerebral haemorrhage requiring surgical intervention to ablate the malformation and hence prevent progression of bleeding. Factors suggestive of underlying vascular malformation are age of patient under 65 years, female gender, non-smoker, lobar location of haemorrhage, intraventricular extension of the haemorrhage and most important absence of history of hypertension [3,4] (Figures 1 and 2). One of factors to bear in mind in intracerebral haemorrhage is cerebral venous thrombosis. Young female with or without use of combined oral contraceptive presenting with intracerebral hemorrhage should have CT venography or (MRV–magnetic resonance venography) to exclude venous thrombosis as the treatment for this condition necessitate use of anticoagulation [5]. For those without known predisposing factors for cerebral venous thrombosis on historical grounds then a search for malignancy needs to be undertaken. The work up of a patient with intracerebral hemorrhage is shown in Table 1.

It is important to recognize the role of anticoagulation and anti-platelet agents in the etiology of intracerebral hemorrhage. Less common is the presence of acquired and congenital coagulation factor deficiencies and intrinsic platelet abnormalities. Those on Vitamin K antagonist anticoagulation (mainly warfarin) with raised International Normalized Ratio (INR) of greater than 1.5 need administration of Vitamin K 5 to 10 mg intravenously slowly as well as giving them Prothrombin Complex Concentrate (PCC) intravenously to bring the INR to 1.3-1.5 [6,7]. The use of Recombinant Activated Factor VIIa (rFVIIa) does normalize INR rapidly but does not restore thrombin generation effectively as PCC and hence this therapy is not recommended for use in Warfarin associated intracerebral haemorrhage [8,9]. In addition, the use of this agent leads more thromboembolic events [10] which obviously complicate the clinical situation.

The role of New Oral Anticoagulants (NOACs)-related intracerebral haemorrhage needs adequate study as the reversing agents developed so far have not been studied in intracranial haemorrhage. The NOACs in present use are dabigatran, rivaroxaban, apixaban and edoxaban. On the other hand, the use of anti-platelets like aspirin and clopidogrel present a difficult clinical challenge in ameliorating the intracerebral haemorrhage. A small study on antiplatelet-related intracranial haemorrhage using platelet transfusion provided promising results with reduction in haematoma expansion and better outcome of such patients [11]. However a larger study is on-going to determine this effect and hopefully should report its findings soon [12].

Figure 1: Non-contrasted CT head showing right hemisphere intracerebral hemorrhage with subarachnoid hemorrhage.
History

1) Time of onset of event
2) Progression of symptoms
3) Vascular risk factors: History of previous intracerebral haemorrhage, hypertension, diabetes mellitus, smoking
4) Medications: Anticoagulant drugs, antiplatelets (e.g., Aspirin, Clopidogrel), anti-hyperensives, sympathomimetic drugs (e.g., Ephedrine, Phenylephrine)
5) Recent head injury
6) Illicit drugs such as Cocaine
7) Seizures
8) Liver disease associated with coagulopathy
9) Haematologic disorders affecting platelets or other coagulation factors

Examination
Document the severity of neurologic deficit so that improvement or deterioration can be followed objectively

Investigations
1) Blood glucose, Prothrombin Time and Activated Partial Thromboplastin Time, toxicology, ECG, troponin, CT Head (non-contrasted) and consider CT angiography +/- venography

Table 1: Work up of patients with Intracerebral haemorrhage.

| Examination | Investigations |
|-------------|----------------|
| Document the severity of neurologic deficit so that improvement or deterioration can be followed objectively | 1) Blood glucose, Prothrombin Time and Activated Partial Thromboplastin Time, toxicology, ECG, troponin, CT Head (non-contrasted) and consider CT angiography +/- venography |

Past practices of leaving acute hypertension post-intracerebral hemorrhage is no longer advocated. This is the most important advance in its clinical management. Systolic blood pressure tend to rise in this condition and reduction to levels of 140 mm of mercury is desirable as higher blood pressures are associated with haematoma expansion with neurological deterioration and ultimately increased mortality and dependency [13].

An important aspect in the clinical management of patients with intracerebral haemorrhage is meticulous attention to associated medical complications which include thromboembolism, hyperglycaemia, pneumonia, respiratory failure and sepsis from other causes. These conditions contribute up to a half of proportion of deaths early in the clinical course of intracerebral haemorrhage. Interestingly the risk of thromboembolism is high in these patients especially women. CLOTs 3 trial [14] showed intermittent pneumatic compression reduced proximal deep vein thrombosis (DVT) while the early use of low molecular heparin, enoxaparin [15,16] found a reduction of pulmonary embolism and mortality but no difference in DVT or cerebral haematoma expansion. Thus any of these two modalities of thromboprophylaxis can be used in such patients.

Control of hyperglycaemia in the absence of history of diabetes mellitus is controversial and further studies are warranted to clarify levels to which glucose needs to be maintained in acute management of intracerebral haemorrhage [17,18]. Another complication is the onset of seizures which should be treated in a similar manner like in other situations but the use of prophylactic anti-convulsants is not warranted [19,20]. Pneumonia leading to respiratory failure and sepsis from other sources is an important complication and should be treated vigorously. It needs to be borne in mind that myocardial infarction leading to cardiac failure as well as arrhythmias are not uncommon in patients with intracerebral haemorrhage [21,22] and these cardiac conditions on their own increase mortality. Hence screening for these conditions by undertaking ECG, Chest X-ray and cardiac troponin is important in the overall assessment of such a patient.

Haemorrhage seeping into the ventricular system is a serious complication invariably leads to secondary hydrocephalus which requires prompt draining using a shunt. Clinical presentation would be with increasing headache and/or drowsiness. At present surgery in evacuation of small supratentorial cortical haematoma is not recommended [23-25] except when the haematoma compresses the nearby neural structures in brain stem or obstruction of 4th ventricle leading to hydrocephalus.

Prediction of the outcome in intracerebral haemorrhage within 24 hours of presentation is futile and it is only after aggressive management in the next 24 to 48 hours when the clinical picture stabilises that a meaningful assessment of the future outcome can be made. Recurrent haemorrhage is not uncommon in the next few years.
if the patient survives the initial insult. Indicators for such recurrence are microbleeds seen in MRI head in the initial presentation, elderly patient, lobar localisation of bleed and on-going anticoagulation. However, for those whose indication for anticoagulation is strong then those with deep haemorrhage (non-lobar) can be cautiously anticoagulated. Those in atrial fibrillation and have sustained intracerebral haemorrhage and cannot be anticoagulated, then occlusion of left atrial appendage by a Watchman Device [26] can provide a reasonable way forward of addressing the issue of future thromboembolism.

Use of mannitol in intracerebral haemorrhage to counter the oedema and mass effect with the reduction of blood pressure has not been shown to produce significant benefit in terms of mortality or major disability [27].

Conclusion

Aggressive clinical management of non-traumatic intracerebral hemorrhage can be a rewarding experience when it leads to decreased morbidity and mortality. Obviously further studies are required to define the precise parameters of clinical interventions like blood glucose control, anti-platelet drug reversal and role of surgery.

References

1. Hemphill JC, Greenberg SM, Anderson CS, Becker K, Bendok BR, et al. (2015) Guidelines for the Management of Spontaneous Intracerebral Hemorrhage: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke 46: 2032-2060.

2. Delcourt C, Huang Y, Arima H, Chalmers J, Davis SM, et al. (2012) Hematoma growth and outcomes in intracerebral hemorrhage: the INTERACT1 study. Neurology 79: 314-319.

3. Bokalis K, Desai A, Zhao W, Gibson D, Gologorsky D, et al. (2012) Computed tomography angiography: improving diagnostic yield and cost effectiveness in the initial evaluation of spontaneous non subarachnoid intracerebral haemorrhage. J Neurosurg 117: 761-766.

4. Delgado Almendoz JE, Schaefer PW, Forero NP, Falla JR, Gonzalez RG, et al. (2009) Diagnostic Accuracy and Yield of Multidetector CT Angiography in the Evaluation of Spontaneous Intraparenchymal Cerebral Haemorrhage. AJNR Am J Neuroradiol 30: 1213-1221.

5. Gazzola S, Aviv RI, Gladstone DJ, Mallia G, Li V, et al. (2008) Vascular and nonvascular mimics of the CT angiography ‘spot sign’ in patients with secondary intracerebral hemorrhage. Stroke 39: 1177-1183.

6. Reiss HR, Meier-Hellmann A, Motsch J, Elias M, Kursten FW, et al. (2007) Prothrombin complex concentrate (Octaplex) in patients requiring immediate reversal of oral anticoagulation. Thromb Res 121: 9-16.

7. Steiner T, Rosand J, Diringer M (2006) Intracerebral hemorrhage associated with oral anticoagulant therapy: current practices and unresolved questions. Stroke 37: 256-262.

8. Tanaka KA, Szlam F, Dickeite G, Levy IH (2008) Effects of prothrombin complex concentrate and recombinant activated factor VII on vitamin K antagonist induced anticoagulation. Thromb Res 122: 117-123.

9. Rosovsky RP, Crowther MA (2008) What is the evidence for the off-label use of recombinant factor VIIa (rFVIIa) in the acute reversal of warfarin. ASH evidence-based review 2008. Hematology Am Soc Hematol Educ Program.

10. Mayer SA, Brun NC, Begtrup K, Broderick J, Davis S, et al. (2008) Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 358: 2127-2137.

11. Naidech AM, Liebling SM, Rosenberg NF, Lindholm PE, Bernstein RA, et al. (2012) Early platelet transfusion improves platelet activity and may improve outcomes after intracerebral haemorrhage. Neurocrit Care 16: 82-87.

12. De Gans K, de Haan RJ, Majoe CR, Koopmann MM, Brand A, et al. (2010) Patch Investigators PATCH: Platelet Transfusion in Cerebral Haemorrhage: Study protocol for a multicentre randomised controlled trial. BMC Neurol 10: 19.

13. Anderson CS, Heeley E, Huang Y, Wang J, Staff C, et al. (2013) Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage. N Engl J Med 368: 2355-2365.

14. Denis M, Sandercock P, Reid I, Graham C, Murray H, et al. (2013) Collaboration, Effectiveness of intermittent pneumatic compression in reduction of deep vein thrombosis in patients who have had a stroke (CLOTS 3): a multicentre randomised controlled trial. Lancet 382: 516-524.

15. Kipthut IC, Staykov D, Kohrmann M, Struffert T, Richter G, et al. (2009) Early administration of low molecular weight heparin after spontaneous intracranial haemorrhage. A safety analysis. Cerebrovascular Disease 27: 146-150.

16. Tetri S, Hakala J, Juvela S, Saloheimo P, Pyhtinen J, et al. (2008) Safety of low dose subcutaneous enoxaparin for prevention of venous thromboembolism after primary intracerebral haemorrhage. Thrombosis Research 23: 206-212.

17. Fogelholm R, Murros K, Rissanen A, Avikainen S, Kimura K, et al. (2005) Hyperglycaemia independently increases the risk of early death in acute spontaneous intracerebral haemorrhage. J Neurol Sci 255: 90-94.

18. Kimura K, Iguchi Y, Inone T, Shibazaki K, Matsumoto N, et al. (2007) Hyperglycaemia independently increases the risk of early death in acute spontaneous intracerebral haemorrhage. J Neurol Sci 255: 90-94.

19. De Herdt V, Dumont F, Hénon H, Derambure P, Vonck K, et al. (2011) Early seizures in intracerebral haemorrhage: incidence, associated factors, and outcome. Neurology 77: 1794-1800.

20. Passero S, Rocchi R, Rossi S, Uliwelli M, Vatti G (2002) Seizures after spontaneous supratentorial intracerebral hemorrhage. Epilepsia 43: 1175-1180.

21. Gattringer T, Niederkorn K, Seyfang L, Seifert-Held T, Simmet N, et al. (2014) Myocardial infarction as a complication in acute stroke: results from the austrian stroke unit registry. Cerebrovasc Dis 37: 147-152.

22. Maramattom BV, Manno EM, Fulgham JR, Jaffe AS, Wijdicks EFM (2006) Clinical Importance of Cardiac Troponin Release and Cardiac Abnormalities in Patients with Supratentorial Cerebral Haemorrhages. Mayo Clin Proc 81: 192-196.

23. Fung C, Murek M, Z’Graggen WJ, Krähenbühl AK, Gauci ES, et al. (2012) Decompressive hemicraniectomy in patients with supratentorial intracerebral hemorrhage. Stroke 43: 3207-3211.

24. Takeuchi S, Wada K, Nagatani K, Otani N, Mori K (2013) Decompressive hemicraniectomy for spontaneous intracerebral hemorrhage. Neurosurg Focus 34: E5.

25. Mendelow AD, Gregson BA, Rowan FN, Murray GD, Golkar A, et al. (2013) Early surgery versus initial conservative treatment in patients with spontaneous supratentorial lobar intracerebral haematoma (STITCH II): a randomised trial. Lancet 382: 397-408.

26. http://www.fda.gov/MedicalDevices. Watchman Device (Accessed on: 15 January 2016).

27. Wang X, Arima H, Yang J, Zhang S, Wu G, et al. (2015) Mannitol and Outcome in Intracerebral Hemorrhage: Propensity Score and Multivariable Intensive Blood Pressure Reduction in Acute Cerebral Hemorrhage Trial 2 Results. Stroke 46: 2762-2767.